Studying TIGIT activity against tumors through the generation of knockout mice

The use of antibodies to block inhibitory receptors, primarily anti-PD1 and CTLA4 (known as checkpoint therapy) revolutionized cancer treatment. However, despite these successes, the majority of cancer patients do not respond to the checkpoint treatment, emphasizing the need for development of addit...

Full description

Bibliographic Details

Published in:	OncoImmunology
Main Authors:	Ahmed Rishiq, Reem Bsoul, Ophir Pick, Ofer Mandelboim
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	Fusion protein nectin PVR TIGIT TIGIT-KO mouse tumor
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2217735